Clinical trial / 2009
In humans, circulating FGF21 was not induced by starvation or ketosis but increased following treatment with PPAR alpha and PPAR delta agonists.
Researchers evaluated plasma FGF21 during a 48-hour fast and 24-hour refeeding in 8 healthy males, a 3-month low-carbohydrate ketogenic diet in 7 obese individuals, and a 2-week treatment with PPAR agonists in 22 overweight or obese males. There was no significant variation in plasma FGF21 during fasting and refeeding, while a 3-month ketogenic diet was associated with a 42% decline in plasma FGF21 levels. Circulating FGF21 increased significantly after treatment with PPAR alpha (39%) and PPAR delta (32%) agonists, but not with a PPAR gamma agonist.
- Study type
- Prospective intervention study across three patient groups
- Who was studied
- 8 healthy males (starvation), 7 obese adults (ketogenic diet), and 22 overweight/obese males (PPAR agonist treatment)
- What was measured
- Fasting plasma FGF21 and serum 3-hydroxybutyrate levels
THE PAPER
Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man.
Christodoulides C, Dyson P, Sprecher D, Tsintzas K, Karpe F. J Clin Endocrinol Metab, 2009.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.